Advertisement
Journal of Oncology Practice  
Search for:
Limit by:
  Browse by Topic or Issue
Home Search or Browse JOP Subscriptions PDA Services E-mail Alerts Customer Service

Journal of Oncology Practice, Vol 2, No 3 (May), 2006: pp. 108-109
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JOP.2.3.108

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

Practical Tips

Focus on Part D Benefits and Chemotherapy

Because this article has no abstract, we have provided an extract of the first 100 words of the full text.

Medicare's prescription drug benefit, also known as the Part D benefit, became effective on January 1, 2006. Although enrollment numbers for the benefit continue to rise, physicians and other health care providers still have questions about the benefit and its implementation. Here are some of the most common questions posed to ASCO's Coding & Reimbursement Hotline.

Question: Many of our patients have a Part D prescription drug plan. It is virtually impossible to know what each prescription plan covers. Are formularies for each plan publicly available somewhere?

Yes. Medicare created a tool, the Formulary Finder, that enables the beneficiary or . . . [Click for More]






About
JOP
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1935-469X. Print ISSN: 1554-7477
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JOP Online